BR112021019826A2 - Síntese otimizada de antígeno de plasmídeo de invasão b livre de célula e composições e métodos de uso relacionados - Google Patents
Síntese otimizada de antígeno de plasmídeo de invasão b livre de célula e composições e métodos de uso relacionadosInfo
- Publication number
- BR112021019826A2 BR112021019826A2 BR112021019826A BR112021019826A BR112021019826A2 BR 112021019826 A2 BR112021019826 A2 BR 112021019826A2 BR 112021019826 A BR112021019826 A BR 112021019826A BR 112021019826 A BR112021019826 A BR 112021019826A BR 112021019826 A2 BR112021019826 A2 BR 112021019826A2
- Authority
- BR
- Brazil
- Prior art keywords
- cell
- free
- antigen
- ipab
- methods
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 8
- 102000036639 antigens Human genes 0.000 title abstract 8
- 108091007433 antigens Proteins 0.000 title abstract 8
- 230000015572 biosynthetic process Effects 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000003786 synthesis reaction Methods 0.000 title abstract 4
- 230000009545 invasion Effects 0.000 title abstract 3
- 239000013612 plasmid Substances 0.000 title abstract 3
- 241000607768 Shigella Species 0.000 abstract 2
- 108010006519 Molecular Chaperones Proteins 0.000 abstract 1
- 102000005431 Molecular Chaperones Human genes 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/25—Shigella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0283—Shigella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
síntese otimizada de antígeno de plasmídeo de invasão b livre de célula e composições e métodos de uso relacionados. a presente divulgação fornece um método livre de células para sintetizar um antígeno antígeno de plasmídeo de invasão b (ipab) associado a uma bactéria shigella compreendendo adição exógena da proteína chaperona de ipgc purificada à mistura de síntese livre de células. a divulgação fornece ainda mutantes do antígeno ipab compreendendo aminoácidos não naturais incorporados durante a síntese livre de células, permitindo a conjugação covalente a um polissacarídeo de antígeno o de shigella. são fornecidos ainda antígenos ipab e conjugados dos mesmos, bem como composições imunogênicas preparadas com os antígenos ipab sintetizados e conjugados dos mesmos e métodos de uso.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962828364P | 2019-04-02 | 2019-04-02 | |
| PCT/US2020/025384 WO2020205584A1 (en) | 2019-04-02 | 2020-03-27 | Optimized cell-free synthesis of invasion plasmid antigen b and related compositions and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021019826A2 true BR112021019826A2 (pt) | 2021-12-07 |
Family
ID=70416548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021019826A BR112021019826A2 (pt) | 2019-04-02 | 2020-03-27 | Síntese otimizada de antígeno de plasmídeo de invasão b livre de célula e composições e métodos de uso relacionados |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220125907A1 (pt) |
| EP (1) | EP3946443A1 (pt) |
| JP (1) | JP2022527206A (pt) |
| KR (1) | KR20210146392A (pt) |
| CN (1) | CN114025789A (pt) |
| AU (1) | AU2020253332A1 (pt) |
| BR (1) | BR112021019826A2 (pt) |
| CA (1) | CA3135489A1 (pt) |
| EA (1) | EA202192401A1 (pt) |
| IL (1) | IL286819A (pt) |
| MA (1) | MA55528A (pt) |
| MX (1) | MX2021012120A (pt) |
| SG (1) | SG11202110803YA (pt) |
| TW (1) | TW202102527A (pt) |
| WO (1) | WO2020205584A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021329889A1 (en) * | 2020-08-19 | 2023-04-20 | Vaxcyte, Inc. | Carrier-protein polysaccharide conjugation methods |
| AU2022221621A1 (en) * | 2021-02-17 | 2023-08-17 | Vaxcyte, Inc. | Purification processes for polysaccharides and polypeptide conjugates thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2163741A1 (en) | 1993-05-28 | 1994-12-08 | Steven Rosenberg | Peptide inhibitors of urokinase receptor activity |
| US5972899A (en) * | 1996-01-25 | 1999-10-26 | New York University | Apoptosis induced by Shigella IpaB |
| CN1912106A (zh) * | 2005-08-09 | 2007-02-14 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种痢疾多价基因工程菌苗及其制备方法 |
| AU2007349883B2 (en) * | 2007-03-27 | 2013-06-27 | The United States Of America As Represented By The Secretary Of The Army, Walter Reed Army Institute Of Research | Artificial invaplex |
| TWI365882B (en) * | 2007-06-15 | 2012-06-11 | Univ Nat Chunghsing | Shigella ipab803 protein, producing method and coding nucleic acid thereof |
| PT2349520T (pt) | 2008-10-27 | 2016-08-16 | Glaxosmithkline Biologicals Sa | Método de purificação para hidrato de carbono de estreptococos grupo a |
| US9040253B2 (en) | 2010-04-14 | 2015-05-26 | Sutro Biopharma, Inc. | Method for enhancing recombinant protein production by cell-free protein expression system |
| US20140294930A1 (en) | 2011-08-04 | 2014-10-02 | The Regents Of The University Of California | STREPTOCOCCAL GlcNAc-LACKING GLYCOPOLYPEPTIDES, CELL WALL CARBOHYDRATES, STREPTOCOCCUS VACCINES, AND METHODS FOR MAKING AND USING THEM |
| KR102018863B1 (ko) | 2012-10-12 | 2019-09-05 | 서트로 바이오파마, 인크. | 개선된 발현을 위해 박테리아 추출물 중 선택 단백질의 단백질분해 불활성화 |
| US9938516B2 (en) | 2013-10-11 | 2018-04-10 | Sutro Biopharma, Inc. | Non-natural amino acid tRNA synthetases for para-methylazido-L-phenylalanine |
| EP3177324A1 (en) * | 2014-08-05 | 2017-06-14 | GlaxoSmithKline Biologicals S.A. | Carrier molecule for antigens |
| CA3048981A1 (en) | 2016-12-30 | 2018-07-05 | Sutrovax, Inc. | Polypeptide-antigen conjugates with non-natural amino acids |
| WO2020010000A1 (en) * | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Improved methods for the preparation of immunogenic conjugates |
| WO2020010016A1 (en) * | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Self-adjuvanted immunogenic conjugates |
-
2020
- 2020-03-27 AU AU2020253332A patent/AU2020253332A1/en active Pending
- 2020-03-27 EA EA202192401A patent/EA202192401A1/ru unknown
- 2020-03-27 CN CN202080040388.1A patent/CN114025789A/zh active Pending
- 2020-03-27 KR KR1020217035696A patent/KR20210146392A/ko unknown
- 2020-03-27 EP EP20721034.5A patent/EP3946443A1/en active Pending
- 2020-03-27 WO PCT/US2020/025384 patent/WO2020205584A1/en unknown
- 2020-03-27 MX MX2021012120A patent/MX2021012120A/es unknown
- 2020-03-27 CA CA3135489A patent/CA3135489A1/en active Pending
- 2020-03-27 BR BR112021019826A patent/BR112021019826A2/pt unknown
- 2020-03-27 MA MA055528A patent/MA55528A/fr unknown
- 2020-03-27 JP JP2021559041A patent/JP2022527206A/ja active Pending
- 2020-03-27 TW TW109110651A patent/TW202102527A/zh unknown
- 2020-03-27 SG SG11202110803YA patent/SG11202110803YA/en unknown
-
2021
- 2021-09-29 IL IL286819A patent/IL286819A/en unknown
- 2021-10-01 US US17/492,190 patent/US20220125907A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021012120A (es) | 2021-11-03 |
| JP2022527206A (ja) | 2022-05-31 |
| US20220125907A1 (en) | 2022-04-28 |
| WO2020205584A1 (en) | 2020-10-08 |
| KR20210146392A (ko) | 2021-12-03 |
| EP3946443A1 (en) | 2022-02-09 |
| TW202102527A (zh) | 2021-01-16 |
| IL286819A (en) | 2021-10-31 |
| CN114025789A (zh) | 2022-02-08 |
| SG11202110803YA (en) | 2021-10-28 |
| EA202192401A1 (ru) | 2022-03-30 |
| CA3135489A1 (en) | 2020-10-08 |
| MA55528A (fr) | 2022-02-09 |
| AU2020253332A1 (en) | 2021-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7248247B2 (ja) | Ｗｔ１抗原ペプチドコンジュゲートワクチン | |
| BR112021019826A2 (pt) | Síntese otimizada de antígeno de plasmídeo de invasão b livre de célula e composições e métodos de uso relacionados | |
| CY1108693T1 (el) | Βελτιωμενες ανοσοενισχυτικες συνθεσεις σαπωνινης και μεθοδοι οι οποιες σχετιζονται με αυτες | |
| CL2021000841A1 (es) | Péptidos y combinación de péptidos de origen no canónico para el uso en la inmunoterapia contra diferentes tipos de cáncer. (divisional de la solicitud no. 202002123) | |
| PT1336621E (pt) | Respostas imunitarias contra antigenios dos vph, suscitadas por composicoes que incorporam um antigenio de vph e uma proteina do stress ou um vector de expressao com aptidao para a expressao destas proteinas | |
| BR9306820A (pt) | Conjugado de um antígeno fracamente imunogênico e um veículo peptideo sintetico vacina processos para melhorar a imunogenicidade de uma molecula de antigeno fracamente imunogenico e para imunizar um hospedeiro mamífero | |
| ES531965A0 (es) | Procedimiento de preparar compuestos vinblastinicos y similares | |
| BR0312472A (pt) | Prepração de uma composição compreendendo uma mistura de complexos de iscom e uso da dita composição | |
| BR0208474A (pt) | método para fornecer um antìgeno alvo ao citossol de uma célula, polipeptìdeo isolado, dna isolado, vetor, composição farmacêutica, métodos para gerar uma resposta imune mediana por célula em um mamìfero, para produzir uma proteìna, e para medir uma resposta imune mediada por célula, e, kit para medir respostas imunes mediadas por célula in vitro | |
| EA200100425A1 (ru) | Новые способы терапевтической вакцинации | |
| CY1114643T1 (el) | Νεοπλασματικες κυτταρικες σειρες nm-f9 (dsm acc2606) και nm-d4 (dsm acc2605), χρησεις αυτων | |
| CY1106789T1 (el) | Γενικος φορεας για στοχευση μοριων σε κυτταρα που εκφραζουν gb3 υποδοχεα | |
| KR890004730A (ko) | G_7rh에 대한 면역반응을 유발시키고 포유동물을 면역 불임시키기 위한 제제 및 방법 | |
| UY27059A1 (es) | Preparaciones para potenciar la inmunogenecidad de antígenos poco inmunogénicos | |
| BR112022006233A2 (pt) | Composições e métodos para síntese in vivo de polipeptídeos não naturais | |
| HRP20140886T1 (hr) | MUTANTI CyaA POLIPEPTIDI I POLIPEPTIDNI DERIVATI PRIKLADNI ZA DOPREMANJE IMUNOGENIÄŚNIH MOLEKULA U STANICU | |
| JP2023549426A (ja) | 免疫応答及び／又は安定性を改善するために共有結合で修飾された抗原 | |
| WO2022232945A1 (en) | Steroid acid-based immunogen enhancers | |
| MX2021014226A (es) | Arn terapeutico para cancer de ovario. | |
| JPWO2014157704A1 (ja) | Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン | |
| CZ344096A3 (en) | Peptides exhibiting immunomodulating effects, pharmaceutical formulations in which such peptides are comprised and their use | |
| US20220249686A1 (en) | Glycoside dual-cleavage linkers for antibody-drug conjugates | |
| BR112013009526A2 (pt) | peptídeos de wdhd1 e vacinas incluindo os mesmos | |
| BR0316271A (pt) | Método para a obtenção de preparados vacinais conjugados multivalentes, composição vacinal multivalente e uso da mesma | |
| DE602006015491D1 (de) | Ein impfstoff |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: VAXCYTE, INC. (US) |